Publicaties

Bloemers J, van Rooij K, de Leede L, Frijlink HW, Koppeschaar HPF, Olivier B, Tuiten A. Single dose sublingual testosterone and oral sildenafil versus a dual-route/dual-release fixed-dose combination tablet: a pharmacokinetic comparison. BJ Clin Pharm 2016. DOI: 10.1111/bcp.12887

Suschinsky KD, Shelley AJ, Gerritsen J, Tuiten A, Chivers ML. The Clitoral Photoplethysmograph: A Pilot Study Examining Discriminant and Convergent Validity. Sex Med. 2015 Dec;12(12):2324-38

van Rooij K. Treatment of female sexual dysfunction: a personalized medicine approach. PhD thesis, 2015. ISBN 978-94-6108-912-0

Bloemers J. Sex, Drugs & Dual Control. A personalized sexual medicine drug development program based on the dual control model of sexual response. PhD thesis, 2014. ISBN 978-90-5335-894-8 

van Rooij K, Poels S, Worst P, Bloemers J, Koppeschaar H, Goldstein A, Olivier B, Tuiten A. Efficacy of testosterone combined with a PDE5 inhibitor and testosterone combined with a serotonin 1A receptor agonist in women with SSRI-induced sexual dysfunction. Eur J Pharmacol, 2014. In print.

Tuiten A, Bloemers J, van Rooij K, Poels S, Gerritsen J, van Ham D, de Leede L, Everard W. Response to “Towards Personalized Medicine: Where is the Evidence?”. J Sex Med, 2014;11:2359-2363.

van Rooij K, de Leede L, Frijlink H, Bloemers J, Poels S, Koppeschaar H, Olivier B, Tuiten A. Pharmacokinetics of a prototype formulation of sublingual testosterone and a buspirone tablet, versus an advanced combination tablet of testosterone and buspirone in healthy premenopausal women. Drugs in R&D, 2014;14:125-32.

Poels S, Bloemers J, van Rooij K, Koppeschaar H, Olivier B, Tuiten A. Two novel combined drug treatments for women with Hypoactive Sexual Desire Disorder.Pharmacology, Biochemistry and Beavior, 2014;121:71-79.

Poels S, Bloemers J, van Rooij K, Koppeschaar H, Olivier B, Tuiten A. Een vernieuwende farmacotherapeutische behandeling voor vrouwen met Hypoactive Sexual Desire Disorder [A new pharmacotherapeutic treatment for women with Hypoactive Sexual Desire Disorder]. Neuropraxis, 2014;18(1):32-45

Bloemers J, Scholte HS, van Rooij K, Goldstein I, Gerritsen J, Olivier B, Tuiten A. Reduced Gray Matter Volume and Increased White Matter Fractional Anisotropy in Women with Hypoactive Sexual Desire Disorder. J Sex Med, 2014;11:753–767

Bloemers J, van Rooij K, Poels S, Goldstein I, Everaerd W, Koppeschaar H, Chivers M, Gerritsen J, van Ham D, Olivier B, Tuiten A. Toward Personalzed Medicine (Part1): Integrating the ''Dual Control Model'' into Differential Drug Treatments for HSDD and FSAD. Journal of Sexual Medicine 2013;10 (3):791-809.

Poels S, Bloemers J, van Rooij K, Goldstein I, Gerritsen J, van Ham D, van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A. Towar Personalized Medicine (Part 2: Testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. Journal of Sexual Medicine 2013;10 (3):810-823.

van Rooij K, Poels S, Bloemers J, Goldstein I, Gerritsen J, van Ham D, van Mameren F, Chivers M, Everaerd W, Koppeschaar H, Olivier B, Tuiten A. Toward Personalized Sexual Medicine (Part 3): Testosterone combined with a Serotonin1A receptor agonist increases sexual satisfaction in women with HSDD and FSAD, and dysfunctional activation of sexual inhibitory mechanisms. Journal of Sexual Medicine 2013;10 (3):824-837.

van Rooij K, Bloemers J, de Leede L,  Goldstein I, Lentjes E, Koppeschaar H, Olivier B, Tuiten A. Pharmacokinetics of three doses of sublingual testosterone in healthy premenopausal women. Psychoneuroendocrinology 2012;37(6):773-81.

Bloemers J, Gerritsen J, Bults R, Koppeschaar H, Everaerd W, Olivier B, Tuiten A. Induction of sexual arousal in women under conditions of institutional and ambulatory laboratory circumstances: a comparative study. Journal of Sexual Medicine 2010; 7(3):1160-76

Gerritsen J, van der Made F, Bloemers J, van Ham D, Kleiverda G, Everaerd W, Olivier B, Levin R, Tuiten A. The clitoral photoplethysmograph: a new way of assessing genital arousal in women. Journal of Sexual Medicine 2009;6(6):1678-87

van der Made F, Bloemers J, van Ham D, El Yassem W, Kleiverda G, Everaerd W, Olivier B, Tuiten A. Childhood sexual abuse, selective attention for sexual cues and the effects of testosterone with or without vardenafil on physiological sexual arousal in women with sexual dysfunction: a pilot study. Journal of Sexual Medicine 2009;6(2):429-39

van der Made F, Bloemers J, Yassem WE, Kleiverda G, Everaerd W, van Ham D, Olivier B, Koppeschaar H, Tuiten A. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. Journal of Sexual Medicine 2009;6(3):777-90

Tuiten A, van Honk J, Verbaten R, Laan E, Everaerd W, Stam H. Can sublingual testosterone increase subjective and physiological measures of laboratory-induced sexual arousal?Archives of General Psychiatry,2002; 59:465–466

Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Archives of General Psychiatry 2000;57(2):149-53

Posters:

Van der Wegen, R., Bloemers, J., de Leede, L., Wouters, G., de Jong, T. & Segers, R. Free testosterone by LC/MSMS - Comparison of ultrafiltration and equilibrium dialysis. European Bioanalysis Forum, Barcalona, 2010

Gerritsen, J., Van Ham, D.M.M., Bloemers, J.M.M., Böcker, K.B.E., Koppeschaar, H.P.F., Everaerd, W.T.A.M., & Tuiten, J.J.A. Testosterone, combined with sildenafil, enhances startles evoked during erotic pictures in sexually dysfunctional women with high sensitivity for sexual cues. 9th Dutch Endo-Neuro-Psycho Meeting, Lunteren, 2011